Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1652W HIGH $15.75
Volume
342.53 K
Value Traded
685.95 K
Short % Float
1.56%
-7.26%Week
-46.74%1 Month
-80%3 Month
-83.75%6 Month
-99.82%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.61 M
EPS (TTM)
-2.05
P/E Ratio
-
Ent. Value
1.35 M
Total Shares
19.48 M
Float Shares
18.48 M
Insiders
9.34%
Institutions
7.78%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MBRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Moleculin Biotech, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Moleculin Biotech, Inc.
944Total events
23Upcoming
174Tier-1 (high impact)
2016 to 2040Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment CompleteAnnamycinFiledTrial
Part A enrollment completed and closed in MIRACLE trial (89 subjects enrolled)
relapsed or refractory acute myeloid leukemia (R/R AML)source ↗
▲PublicationAnnamycinFiledPresentation
Peer-reviewed publication of pooled cardiac safety analysis of Annamycin in Frontiers in Cardiovascular Medicine
acute myeloid leukemia (AML) and metastatic soft tissue sarcoma (STS)source ↗
▲Pooled AnalysisAnnamycinFiledClinical Data
Pooled analysis of five clinical trials shows no cardiotoxicity with Annamycin at high cumulative doses
acute myeloid leukemia (AML) and metastatic soft tissue sarcoma (STS)source ↗
●Poster PresentationAnnamycinFiledPresentation
Presentation of Annamycin preclinical data at AACR Conference on Pancreatic Cancer
pancreatic cancersource ↗
●AbstractAnnamycinFiledPresentation
Abstract for Annamycin pancreatic cancer presentation published in Cancer Research supplement
pancreatic cancersource ↗
▲Preclinical PoCAnnamycinFiledPreclinical
Annamycin preclinical data show antitumor activity partially mediated by CD8+ T cells in pancreatic cancer models
pancreatic cancersource ↗
▲Patent GrantedAnnamycinFiledIP / Competition
Mexican Patent Office grants Patent No. 436849 for lung-targeted liposomal Annamycin
relapsed or refractory acute myeloid leukemia (AML); soft tissue sarcoma (STS) lung metastasessource ↗
●AbstractAnnamycinFiledPresentation
Abstract for Annamycin pancreatic cancer presentation published in Cancer Research supplement
pancreatic cancersource ↗
●R&D DayPresentation
Management on-site at H.C. Wainwright 28th Annual Global Investment Conference for one-on-one investor meetings
●Oral PresentationAnnamycinFiledPresentation
Invited lecture on organotropism-guided exploration of Annamycin anticancer properties at Hirszfeld Institute
cancersource ↗
●R&D DayPresentation
Moleculin pre-recorded presentation from H.C. Wainwright 28th Annual Global Investment Conference available on-demand
●Oral PresentationAnnamycinFiledPresentation
Annamycin organotropism and antitumor activity presentation at XIII Congress of the Polish Medical Diaspora
hard-to-treat cancerssource ↗
●Oral PresentationPresentation
CEO participated in Virtual Investor 'Why Now' on-demand conference
▼Equity OfferingCorporate
Raised $9.3 million in financing proceeds subsequent to quarter-end
▲Trial InitiationAnnamycinFiledTrial
MIRACLE trial begun
relapsed or refractory acute myeloid leukemiasource ↗
▲Interim AnalysisAnnamycinFiledTrial
Preliminary blinded interim data from Part A of MIRACLE trial
relapsed or refractory acute myeloid leukemiasource ↗
▲Enrollment MilestoneAnnamycinFiledTrial
Enrollment reaches 74 of 90 subjects in Part A
relapsed or refractory acute myeloid leukemiasource ↗
▲Safety Data UpdateAnnamycinFiledClinical Data
No evidence of cardiotoxicity observed in MIRACLE trial
relapsed or refractory acute myeloid leukemiasource ↗
▲Topline ReadoutAnnamycinFiledClinical Data
Positive preliminary unblinded efficacy results from first 45 patients in Part A of MIRACLE trial
relapsed or refractory acute myeloid leukemia (R/R AML)source ↗
▲Interim AnalysisAnnamycinFiledTrial
Positive preliminary unblinded efficacy results from first 45 patients in Part A of MIRACLE trial
relapsed or refractory acute myeloid leukemiasource ↗
▼Equity OfferingCorporate
Raised $9.3 million in financing proceeds subsequent to quarter-end
▲Interim AnalysisAnnamycinFiledTrial
Positive interim results from first 45 patients in Part A
relapsed or refractory acute myeloid leukemiasource ↗
●Enrollment UpdateAnnamycinFiledTrial
67 of 90 Part A patients enrolled (74%)
relapsed or refractory acute myeloid leukemiasource ↗
▲Enrollment MilestoneAnnamycinFiledTrial
45th subject enrolled in MIRACLE trial
relapsed or refractory acute myeloid leukemiasource ↗
▲Interim AnalysisAnnamycinFiledTrial
Unblinded interim analysis at n=45 announced
relapsed or refractory acute myeloid leukemiasource ↗
▲Oral PresentationAnnamycinFiledPresentation
Presented data at the 2026 ASCO Annual Meeting demonstrating no detectable cardiotoxicity
relapsed or refractory acute myeloid leukemiasource ↗
◆Poster PresentationAnnamycinFiledPresentation
Abstract accepted for poster presentation at 2026 ASCO Annual Meeting on pooled cardiac safety data for Annamycin
Acute Myeloid Leukemia (AML) and Soft Tissue Sarcomasource ↗
▲Poster PresentationAnnamycinFiledPresentation
Poster presentation at ASCO 2026 on cardiac safety of L-annamycin at high cumulative anthracycline exposure
acute myeloid leukemia, soft tissue sarcomasource ↗
▲Enrollment MilestoneAnnamycinFiledTrial
Enrollment of first 45 subjects achieved in MIRACLE trial
relapsed/refractory acute myeloid leukemiasource ↗
▲Patent GrantedAnnamycinFiledIP / Competition
Hong Kong patent granted for method of reconstituting liposomal Annamycin
▲Poster PresentationAnnamycinFiledPresentation
Preclinical data presented at AACR 2026 showing Annamycin extends survival by >60% in metastatic pancreatic cancer models
pancreatic ductal adenocarcinomasource ↗
▲Interim AnalysisAnnamycinFiledTrial
Positive interim results from first 45 patients in Part A
relapsed or refractory acute myeloid leukemiasource ↗
◆Topline ReadoutAnnamycinFiledClinical Data
First Phase 3 clinical data release expected later this quarter
relapsed or refractory acute myeloid leukemiasource ↗
▲Enrollment MilestoneAnnamycinFiledTrial
45th subject enrolled in MIRACLE trial
relapsed or refractory acute myeloid leukemiasource ↗
▲Safety Data UpdateAnnamycinFiledClinical Data
Independent assessment for absence of cardiotoxicity in 90 subjects
Varioussource ↗
▲Partnership / LicenseAnnamycinFiledCorporate
Research collaboration with CIC biomaGUNE for intra-arterial delivery in GBM
Glioblastoma Multiforme (GBM)source ↗
▲Full ResultsWP1066Clinical Data
Positive Phase 1 results for WP1066 in pediatric brain tumors
Pediatric Recurrent Malignant Brain Tumorssource ↗
◆Enrollment CompleteAnnamycinFiledTrial
Completion of treatment for first 45 patients in MIRACLE Study expected in near term
Relapsed or Refractory Acute Myeloid Leukemiasource ↗
◆Interim AnalysisAnnamycinFiledTrial
Interim unblinding to evaluate safety and efficacy after first 45 patients
Relapsed or Refractory Acute Myeloid Leukemiasource ↗
Past FDA Catalysts and PDUFA Decisions
How MBRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-01 | Annamycin (naxtarubicin) | Phase 2b/3 data readout | Phase 2b/3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 69%
Micro Cap(rank 456 of 660)
Percentile Rank
Moleculin Biotech, Inc. faces pipeline headwinds (30/100), with $340M risk-adjusted pipeline value, led by Annamycin in Acute Myeloid Leukaemia (AML) (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Annamycin Small moleculeNCT06788756 | Acute Myeloid Leukaemia (AML) | Phase 2 | RECRUITING | 312 | Aug 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every MBRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Annamycin Fast TrackOrphan | relapsed or refractory acute myeloid leukemia (AML) | Phase 2/3 | 2026-08-27 | encouraging interim resultsRead More | Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Foster Jonathan P.Officer (Chief Financial Officer) | Buy | 293,333 305,673 held | $0.00 | 08/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MBRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MBRX for Q2 2026. | ||||
MBRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MBRX ranks across every disease it competes in
Competitive Position is a premium feature
See how MBRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMBRX News
MBRX▲ +7.5%today
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
Moleculin Biotech will present at the 2026 Maxim Growth Summit, discussing its oncology pipeline and the MIRACLE trial for Annamycin in treating relapsed or refractory acute myeloid leukemia. The trial's Part A enrollment is complete, with data readout expected in Q1 2027. CEO Walter Klemp will lead the presentation, highlighting the company's advancements.
Read more →MBRX▼ -7.5%on this news
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
Moleculin Biotech has successfully completed enrollment in Part A of its Phase 2/3 MIRACLE trial for Annamycin in R/R AML, with 89 subjects enrolled. This rapid enrollment reflects strong investigator engagement and the unmet need in R/R AML. The company anticipates a comprehensive data readout in Q1 2027, which is expected to provide crucial efficacy insights.
Read more →MBRX▼ -5.4%on this news· ran to -16% by day 3shared move
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
Moleculin Biotech announced the publication of a peer-reviewed analysis confirming the cardiac safety of Annamycin. The study, which pooled data from five clinical trials, showed no evidence of cardiotoxicity even at high cumulative doses. This finding supports the continued development of Annamycin as a safer alternative to traditional anthracyclines, which are limited by cardiotoxicity risks.
Read more →MBRXAnnamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
Moleculin Biotech presented new preclinical data at the AACR Conference, showing that Annamycin's antitumor activity in pancreatic cancer is partially mediated by CD8+ T cells. This suggests that Annamycin may not only directly kill cancer cells but also enhance immune response against typically 'cold' tumors. The findings could pave the way for combination therapies, although results in humans remain uncertain.
Read more →MBRX▼ -6.6%on this newsshared move
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Moleculin Biotech has been granted a Mexican patent for its lung-targeted liposomal Annamycin, which enhances its global intellectual property portfolio. This patent, valid until 2040, supports the company's ongoing MIRACLE trial for relapsed or refractory acute myeloid leukemia (AML). The patent strengthens Moleculin's strategy to expand Annamycin's commercial potential across various oncology indications.
Read more →MBRX▲ +8.4%on this news
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
Moleculin Biotech announced that new data on its lead drug candidate, Annamycin, will be presented at three scientific venues in September 2026. The presentations will focus on Annamycin’s organotropism, its mechanism of action targeting topoisomerase II, and its potential to activate immune responses in pancreatic cancer treatment. This showcases the drug's development for challenging cancers.
Read more →MBRX▼ -13.8%on this newsshared move
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
Moleculin Biotech, Inc. announced that its presentation from the H.C. Wainwright Conference is now available for on-demand viewing. The presentation covers recent corporate and clinical developments, including the advancement of its lead program, Annamycin, for treating acute myeloid leukemia. Management will also be available for one-on-one meetings at the conference in New York.
Read more →MBRX▲ +14.8%on this news
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
Moleculin Biotech participated in the Virtual Investor 'Why Now' conference, where CEO Walter Klemp discussed the company's clinical advancements, particularly the promising interim results from the Phase 2/3 MIRACLE trial of Annamycin for treating relapsed or refractory acute myeloid leukemia (AML). The presentation highlighted Annamycin's unique clinical profile and the importance of the upcoming interim analysis as a potential catalyst for the company's future.
Read more →MBRX▲ +7.2%on this news
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
Moleculin Biotech reported positive interim results from its pivotal Phase 2/3 MIRACLE trial, showing complete remission rates in relapsed/refractory AML patients that are three times higher than the control group. The trial is on track to complete enrollment of 90 patients by September 2026, with data readouts expected between December 2026 and February 2027. The company also highlighted its strong cash position, expected to fund operations into early 2027.
Read more →MBRX▼ -59.4%on this news
Moleculin Announces Pricing of $9.3 Million Public Offering
Moleculin Biotech, Inc. has announced a public offering priced at $9.3 million, involving 12,376,667 shares and associated warrants. The proceeds will be used to advance the clinical development of Annamycin, their lead therapeutic candidate. The offering is expected to close around August 3, 2026, pending customary conditions.
Read more →MBRX▼ -60.8%on this newsshared move
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Moleculin Biotech reported positive interim results from its Phase 2/3 MIRACLE trial, showing a 37% composite complete remission rate among patients with relapsed or refractory acute myeloid leukemia who previously failed venetoclax treatment. The trial is nearing completion of Part A, with final results expected between December 2026 and February 2027. Notably, there is no observed cardiotoxicity associated with Annamycin, enhancing its profile compared to traditional therapies.
Read more →MBRX▼ -9.1%on this news
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
Moleculin Biotech's CEO Walter Klemp discussed the promising preliminary results from the first 45 patients in the Phase 2/3 MIRACLE trial for Annamycin, aimed at treating relapsed or refractory acute myeloid leukemia. The early data suggests potential efficacy and commercial opportunities, although the results are based on a limited sample size and have not yet reached statistical significance. The company is optimistic about the drug's future, pending further trials and necessary financing.
Read more →MBRX▼ -9.1%on this newsshared move
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor “What This Means” Segment
Moleculin Biotech's CEO Walter Klemp discussed positive preliminary results from the Phase 2/3 MIRACLE trial for Annamycin in treating relapsed or refractory acute myeloid leukemia. The early efficacy trends observed across treatment arms are encouraging, and the company is optimistic about the commercial potential of Annamycin. However, the results are based on a limited patient sample and require further validation.
Read more →MBRX▼ -21.8%on this news· ran to -33% by day 3shared move
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
Moleculin Biotech reported positive interim results from its Phase 2/3 MIRACLE trial, where both Annamycin treatment arms demonstrated significantly higher complete remission rates compared to the control arm in patients with relapsed or refractory acute myeloid leukemia. The interim analysis showed remission rates of 43% and 36% for Annamycin versus 12% for control, with ongoing enrollment in the trial. Despite the promising results, the analysis did not achieve statistical significance, and further data is needed as the trial progresses.
Read more →MBRXIndependent Market Research Finds Strong Physician Intent to Prescribe Moleculin’s Annamycin in Relapsed/Refractory AML
Moleculin Biotech's Annamycin shows strong physician interest for treating relapsed/refractory acute myeloid leukemia (R/R AML), with oncologists rating a likelihood to prescribe of 6 out of 7. Key factors include its efficacy, safety profile, and potential to bridge patients to bone marrow transplants. Payers also recognize its value in addressing significant unmet needs in this patient population.
Read more →MBRXMoleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
Moleculin Biotech's CEO, Walter Klemp, announced the enrollment of the 45th subject in the pivotal Phase 2B/3 MIRACLE trial for Annamycin combined with cytarabine, targeting relapsed or refractory acute myeloid leukemia. This milestone signals the upcoming interim data unblinding, expected in mid-2026, which could be crucial for the company's future. The company also highlighted the need for additional financing to continue its clinical trials.
Read more →MBRXMoleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Moleculin Biotech presented new data at the 2026 ASCO Annual Meeting, showcasing the cardiac safety profile of Annamycin, its lead drug candidate. A pooled analysis from five clinical trials revealed no detectable cardiotoxicity despite high cumulative doses. The findings support Annamycin's potential to allow continued use of anthracyclines without the associated cardiac risks.
Read more →MBRXMoleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
Moleculin Biotech announced that its abstract on the cardiac safety of Annamycin has been accepted for poster presentation at the 2026 ASCO Annual Meeting. The findings indicate that Annamycin does not induce cardiotoxicity even at high cumulative doses, supporting its potential as a safer anthracycline therapy. The presentation will take place on May 30, 2026, in Chicago.
Read more →MBRXMoleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
Moleculin Biotech, Inc. (MBRX) reported financial results for Q1 2026, highlighting promising progress in the pivotal MIRACLE trial for Annamycin in relapsed/refractory acute myeloid leukemia (AML). The trial has achieved a 40% complete remission rate and has surpassed the enrollment milestone for the first interim analysis. The company successfully raised $8.3 million to support its operations through mid-2026. Moleculin is also expanding its clinical operations in the US and Europe while bolstering its intellectual property strategy.
Read more →About Moleculin Biotech, Inc.
Headquarters5300 MEMORIAL DRIVE, HOUSTON, TX, 77007
BIOPHARMAWATCH ELITE PLUS
Trade the next MBRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime